What are the prognosis and survival rates for splenic marginal zone lymphoma (SMZL)?
SMZL is considered an indolent (slow-growing) lymphoma, which generally means people tend to have a positive outlook and can live for many years after diagnosis.
Here are the key survival statistics:
- 5-year survival rate: 77% of people Show Full Answer
What are the prognosis and survival rates for splenic marginal zone lymphoma (SMZL)?
SMZL is considered an indolent (slow-growing) lymphoma, which generally means people tend to have a positive outlook and can live for many years after diagnosis.
Here are the key survival statistics:
- 5-year survival rate: 77% of people are still alive
- 10-year survival rate: 60% of people are still alive However, it's important to know that about 3 in 10 people with SMZL can develop a more aggressive, faster-growing form. There's also a chance SMZL can transform into a more aggressive type of lymphoma over time.
Factors that may point to a less favorable outlook include:
- Older age
- Enlarged lymph nodes
- Cancer cells spreading outside the spleen and bone marrow
- Certain gene mutations
- High white blood cell counts
- Low red blood cell or platelet counts
- Poor overall health Currently, SMZL cannot be cured, but many people are successfully managed with treatments like rituximab and chemotherapy. Newer options like BTK inhibitors are also improving outcomes for those whose lymphoma has relapsed or stopped responding to treatment.
Talking with your healthcare team is the best way to understand what your personal prognosis looks like, as individual factors can make a big difference.
May 4
Join
Your Privacy Choices
